Product Name: ILK (340-346) pS343
Product Number: PE-04AVE01
| Size: | $US |
Peptide Name: ILK (340-346) pS343
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S343 phosphorylation stimulates phosphotransferase activity. Phosphorylation regulates molecular association, including inducing interaction with Akt1.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VKF(pS)FQC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S343 phosphorylation stimulates phosphotransferase activity. Phosphorylation regulates molecular association, including inducing interaction with Akt1.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VKF(pS)FQC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Storage Conditions: -20°C
Scientific Background: ILK (ILK1) is a protein-serine/threonine kinase of the TKL group and MLK family. It has a critical role in the regulation of integrin-mediated signal transduction. It is stimulated rapidly but transiently by both cell fibronectin interactions, as well as by insulin, in a PI3-K-dependent manner, likely via the binding of PtdIns(3,4,5)P3 with a PH-like domain of ILK. It is a component of the complex ILK-PINCH, which is thought to be a primary point for the convergence of integrin- and growth-factor signalling as well as a regulator of cell architecture, integrin-mediated adhesion, and anchorage-dependent cell growth in epithelial cells. Downstream targets of ILK include the beta-1 and beta-3 integrin subunits as well as Akt1 and GSK3b. The ILK mutation, H99D can modulate interactions with LIMS1. An E359K mutation can inactivate ILK. ILK appears to be a oncoprotein (OP), but is relatively low rate of mutation in human cancers supports its assignment as a tumour requiring protein (TRP). It has been implicated as an oncoprotein due to its ability to activate Akt isoforms, although it has weak phosphotransferase activity that is stimulated in vitro with manganese.
© Kinexus Bioinformatics Corporation 2017